Protocol Ledger

NCT07207811 · Phase III · RECRUITING

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Interventional Phase III clinical trial protocol NCT07207811 sponsored by Novo Nordisk in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-02 Enrollment: 1,280 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07207811
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,280 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07207811
Protocol FieldVerified Registry Value
NCT IdentifierNCT07207811
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,280 participants (ESTIMATED)
Registered Start Date2025-10-02
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI